Clinical Trials

Kemwell Biopharma announced that it has manufactured and supplied drug substance using its state-of-the-art mammalian cell culture plant in India for clinical trials that will be…
Read More...

Acasti Pharma announced that it has received an invitation to present the CaPre (omega-3 phospholipid) study results at the National Lipid Association Scientific Sessions in…
Read More...

Concert Pharmaceuticals received notice from the U.S. FDA that its CTP-543 Phase 2a clinical trial for alopecia areata has been placed on clinical hold. The FDA had previously…
Read More...

CytoDyn In. announced the treatment of the first patient suffering from GvHD(Graft versus Host Disease) with use of PRO 140 during its clinical trial Phase 2. The multicenter,…
Read More...

DelMar Pharmaceuticals  announced that it has signed collaboration agreement with PRA Health Sciences for company's Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).…
Read More...

Biogen has acquired Remedy Pharmaceuticals’ Phase 3 candidate CIRARA (intravenous glyburide). The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of…
Read More...

NantCell and NantKwest announced that the FDA has authorized NANT Cancer Vaccine for clinical trial enrollment (ClinicalTrials.gov NCT03136406). The NANT Cancer Vaccine is the first…
Read More...

Cosmo Pharmaceuticals announced that clinical trial of Eleview in comparison to a standard saline solution in subjects undergoing Endoscopic Mucosal Resection (EMR) of colonic lesions…
Read More...

Teva Pharmaceutical and Active Biotech announced that the results from the CONCERTO trial did not meet primary endpoint. The trial was based on patients with relapsing-remitting…
Read More...

Corvus Pharmaceuticals has expanded its clinical collaboration with Genentech. Under the new agreement, CPI-444 administered in combination with atezolizumab (Tecentriq) will be…
Read More...

SGS announced the successful completion of a Phase I clinical trial of a new strain of influenza virus in healthy volunteers. The study used a GMP-manufactured, non-hemagglutinating,…
Read More...

BioPharmX announced that it achieved primary endpoint in its phase 2b clinical trial evaluating BPX-011. From the topline results for the study's primary endpoint, BioPharmX…
Read More...

Propanc Biopharma provided an update on the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for First-In-Human studies. PRP is a solution for…
Read More...

Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation of…
Read More...

Medicortex Finland Oy, a biotechnology company developing a diagnostic kit for brain injury detection based on a medical breakthrough biomarker, recently completed analyzing the results…
Read More...

Concert Pharmaceuticals announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which…
Read More...

Neurotrope, Inc. announced positive top-line results from its Phase 2 study (-202 Study) of Bryostatin-1 in patients with moderate to severe Alzheimer's disease (AD), a population not…
Read More...

enGene announced that Theresa Podrebarac, has been appointed as the  Chief Medical Officer of the company. He will be responsible for designing and executing clinical development plan…
Read More...

TESARO an oncology-focused biopharmaceutical company, announced that following the recent identification of a fixed dose and patient-centric dosing schedule, the ongoing clinical trial…
Read More...

Merck announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus…
Read More...